| Literature DB >> 20046481 |
Cigdem Celik1, Neslihan Arhun, Kivanc Yamanel.
Abstract
OBJECTIVES: The purpose of this study was to evaluate and compare the 12 month clinical performances of two different posterior composites in Class I and Class II restorations.Entities:
Keywords: Clinical evaluation; Nanohybrid composites; Posterior composites
Year: 2010 PMID: 20046481 PMCID: PMC2798791
Source DB: PubMed Journal: Eur J Dent
Material descriptions, batch numbers and manufacturers of the materials used in the study.
| Futurabond NR | Dentin Bonding Agent: Light-curing self-etch bond reinforced with nanofillers | Liquid A: methacryl phosphorus acid ester and carbonic acid modified methacrylic ester | Voco GmbH Germany | 610456 |
| XenoIII | Dentin Bonding Agent Single step self-etch Fluoride releasing adhesive | Liquid B: Phosphoric acid modified polymethacrylate resin, Mono fluoro | Dentsply Caulk Germany | 0505001099 |
| Grandio | Resin Composite Universal Light curing Nanohybrid resin composite | 87% w/w (71% volume) inorganic nano-hybrid filler, BisGMA, UDMA, TEGDMA | Voco GmbH Germany | 620492 |
| Quixfil | Resin Composite Posterior resin composite | Camphorquinone Ethyl-4-dimethylaminobenzoate | Dentsply Caulk Germany | 0607001089 |
HEMA: 2-hydroxyethyl methacrylate; BHT: Butylated hydroxy toluene; TEGDMA: Triethylenglycoldimethacryate; BisGMA: bisphenol-A-diglycidylether dimethacrylate; UDMA: Urethane dimethacrylate
Distribution of materials and tooth locations of the restorations.
| Quixfil | 14 | 6 | 3 | 7 | 9 | 2 |
| Grandio | 11 | 8 | 5 | 10 | 3 | 4 |
| TOTAL | 25 | 14 | 8 | 17 | 12 | 6 |
Modified USPHS evaluation criteria.
| Retention | Alfa: No loss of restorative material |
| Charlie: Any loss of restorative material | |
| Color Match | Alfa: Matches tooth |
| Bravo: Acceptable mismatch | |
| Charlie: Unacceptable mismatch | |
| Marginal Discoloration | Alfa: No discoloration |
| Bravo: Discoloration without | |
| Charlie: Discoloration with penetration in pulpal direction | |
| Marginal Adaptation | Alfa: Closely adapted, no visible crevice |
| Bravo: Visible crevice, explorer will penetrate | |
| Charlie: Crevice in which dentin is exposed | |
| Secondary Caries | Alfa: No caries present |
| Charlie: Caries present | |
| Surface Texture | Alfa: Enamel-like surface |
| Bravo: Surface rougher than enamel, clinically acceptable | |
| Charlie: Surface unacceptably rough | |
| Anatomic Form | Alfa: Continuous |
| Bravo: Slight discontinuity, clinically acceptable | |
| Charlie: Discontinuous, failure | |
| Postoperative sensitivity | Alfa: Not present |
| Bravo: sensitive but diminishing in intensity | |
| Charlie:constant sensitivity, not diminishing in intensity |
Summary of the clinical findings of Ryge criteria at the end of 12 months.
| Baseline | 41 | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) |
| 6 months | 41 | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) |
| 12 months | 41 | 39(95%) | 2(5%) | 0(0%) | 37(90%) | 4(10%) | 0(0%) | 41(100%) | 0(0%) | 40(98%) | 1(2%) | 0(0%) |
| Quixfil + Xeno III | n* | A | B | C | A | B | C | A | C | A | B | C |
| Baseline | 41 | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) |
| 6 months | 41 | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) | 41(100%) | 0(0%) | 41(100%) | 0(0%) | 0(0%) |
| 12 months | 41 | 41(100%) | 0(0%) | 0(0%) | 40(98%) | 1(2%) | 0(0%) | 39(95%) | 2(5%) | 41(100%) | 0(0%) | 0(0%) |
HEMA: 2-hydroxyethyl methacrylate; BHT: Butylated hydroxy toluene; TEGDMA: Triethylenglycoldimethacryate; BisGMA: bisphenol-A-diglycidylether dimethacrylate; UDMA: Urethane dimethacrylate